Assessment Status | Full HTA submission received from Applicant |
HTA ID | 22012 |
Drug | Finerenone |
Brand | Kerendia® |
Indication | For the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. |
Assessment Process | |
Rapid review commissioned | 21/02/2022 |
Rapid review completed | 15/03/2022 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of finerenone compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 01/04/2022 |
Pre-submission consultation with Applicant | 24/05/2022 |
Full submission received from Applicant | 10/11/2022 |